In silico mutagenesis for improving activity of cytosine deaminase of bifidobacterium breve: approach towards effective pro-drug gene therapy in colorectal cancer
Solitary Colorectal cancer (CRC) is the third most type of cancer that leading causes of morbidity and mortality worldwide. Among the recent therapeutic strategies the application of probiotics for treating cancer cell is most promising one. Bifidobacterium breve is a probiotic that can be applied in treating tumor cell (for its anaerobic nature) with least adverse effect. Prodrug/enzyme therapy is one of its mechanisms of therapeutic potentiality which contains 5FC and cytosine deaminase (CD).